Immunoediting in Cancer Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 13 April 2025 | Viewed by 31
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer cells develop immune escape or avoidance characteristics to achieve uninterrupted growth, proliferation, and metastasis or spread to distant organs. This immune escape of cancer cells is called cancer immunosurveillance. In addition to cancer immunosurveillance, which is only one dimension of a cancer and immune system relationship. For example, along with cancer immunosurveillance, they also induce a process called cancer immunoediting, where cancer cells modify the anti-tumor immune response and immune cells to support their growth, proliferation and metastasis. The cancer immunoediting phase comprises three potential Es: elimination, equilibrium and escape. The elimination phase comprises classical immunosurveillance, the equilibrium phase comprises the period of immune-mediated latency due to incomplete destruction of cancer cells during the elimination phase, and the escape phase includes final tumor growth by overcoming/limiting the antitumor immune response during the equilibrium phase. Thus, understanding cancer immunoediting is critical to develop novel immunomodulatory and immunotherapies. This Special Issue is a good platform for researchers involved in cancer immunotherapies and understating the cancer immunoediting to design better immunotherapies.
Dr. Vijay Kumar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- cancer immunology
- immunosurveillance
- immunoediting
- immunotherapy
- immunomodulation
- immunometabolism
